8
Participants
Start Date
October 10, 2023
Primary Completion Date
March 31, 2025
Study Completion Date
May 9, 2026
Cytarabine
Given IV and IT
Fludarabine
Given IV
Leucovorin
Give PO or IV
Triple Intrathecal Chemotherapy
Given IT
Uproleselan
Given IV
Memorial Sloan Kettering Cancer Center, New York
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Children's Hospital of Alabama, Birmingham
Saint Jude Children's Research Hospital, Memphis
Cincinnati Children's Hospital Medical Center, Cincinnati
Riley Hospital for Children, Indianapolis
C S Mott Children's Hospital, Ann Arbor
University of Minnesota/Masonic Cancer Center, Minneapolis
Lurie Children's Hospital-Chicago, Chicago
Washington University School of Medicine, St Louis
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Children's Hospital Colorado, Aurora
Children's Hospital Los Angeles, Los Angeles
Children's Hospital of Orange County, Orange
UCSF Medical Center-Mission Bay, San Francisco
Seattle Children's Hospital, Seattle
Children's Oncology Group
NETWORK
LLS PedAL LLC
UNKNOWN
National Cancer Institute (NCI)
NIH